Engineering of affibody molecules for therapy and diagnostics

Methods in Molecular Biology

Volumn 899, Issue , 2012, Pages 103-126

  Feldwisch, Joachim ^a   Tolmachev, Vladimir ^b  

^a Affibody AB   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

ABD, Molecular Imaging; Affibody molecules; Affinity ligand; Albumin binding domain; Biodistribution; Chelator; Radionuclides; Scaffold protein; Site specific modification; Targeted therapy

Indexed keywords

ALBUMINOID; DIAGNOSTIC AGENT; LIGAND; PEPTIDE; PROTEIN; RADIOISOTOPE;

AFFINITY LABELING; ARTICLE; CHEMISTRY; GENETICS; HUMAN; METHODOLOGY; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN TERTIARY STRUCTURE;

AFFINITY LABELS; ALBUMINS; HUMANS; LIGANDS; MOLECULAR IMAGING; MOLECULAR TARGETED THERAPY; PEPTIDES; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN STRUCTURE, TERTIARY; PROTEINS; RADIOISOTOPES;

ESCHERICHIA COLI;

EID: 84864133023     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-921-1_7     Document Type: Article

References (88)

1. An Z (2010) Monoclonal antibodies - a proven and rapidly expanding therapeutic modality for human diseases. Protein Cell 1:319-330
2. Kenanova V, Wu AM (2006) Tailoring antibodies for radionuclide delivery. Expert Opin Drug Deliv 3:53-70
3. Mohlmann S et al (2011) Site-specific modi fi cation of ED-B-targeting antibody using intein-fusion technology. BMC Biotechnol 11:76
4. Friedman M, Stahl S (2009) Engineered af fi nity proteins for tumour-targeting applications. Biotechnol Appl Biochem 53:1-29
5. Löfblom J et al (2010) Af fi body molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 584:2670-2680
6. Zoller F, Haberkorn U, Mier W (2011) Miniproteins as phage display-scaffolds for clinical applications. Molecules 16:2467-2485
7. Baum RP et al (2010) Molecular imaging of HER2-Expressing malignant tumors in breast cancer patients using synthetic 111 In- or 68 Galabeled Af fi body molecules. J Nucl Med 51:892-897
8. Tolcher AW et al (2011) Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fi bronectin. Clin Cancer Res 17:363-371
9. Uhlén M et al (1984) Complete sequence of the staphylococcal gene encoding protein A. A gene evolved through multiple duplications. J Biol Chem 259:1695-1702
10. Moks T et al (1986) Staphylococcal protein A consists of fi ve IgG-binding domains. Eur J Biochem 156:637-643
11. Nilsson B et al (1987) A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng 1:107-113
12. Arora P, Oas TG, Myers JK (2004) Fast and faster: A designed variant of the B-domain of protein A folds in 3 microsec. Protein Sci 13:847-853
13. Nord K et al (1995) A combinatorial library of an alpha-helical bacterial receptor domain. Protein Eng 8:601-608
14. Orlova A et al (2006) Tumor imaging using a picomolar af fi nity HER2 binding Af fi body molecule. Cancer Res 66:4339-4348
15. Grönwall C et al (2007) Selection and characterization of Af fi body ligands binding to Alzheimer amyloid beta peptides. J Biotechnol 128:162-183
16. Lindborg M et al (2011) Engineered highaf fi nity Af fi body molecules targeting plateletderived growth factor receptor beta in vivo. J Mol Biol 407:298-315
17. Tolmachev V (2008) Choice of radionuclides and radiolabeling techniques. In: Stigbrand T (ed) Targeted radionuclide tumor therapy - biological aspects. Springer Science + Business Media B.V, Dordrecht, pp 145-174
18. Mattes MJ et al (1994) Processing of antibodyradioisotope conjugates after binding to the surface of tumor cells. Cancer 73:787-793
19. Shih LB et al (1994) The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: A comparison of nine radiolabels. J Nucl Med 35:899-908
20. Press OW et al (1996) Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 56:2123-2129
21. Orlova A et al (2000) Cellular processing of 125 I- and 111 In-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells. Nucl Med Biol 27:827-835
22. Tolmachev V, Orlova A, Lundqvist H (2003) Approaches to improve cellular retention of radiohalogen labels delivered by internalising tumour-targeting proteins and peptides. Curr Med Chem 10:2447-2460
23. Behr TM et al (2001) Imaging tumors with peptide-based radioligands. Q J Nucl Med 45:189-200
24. Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24:389-427
25. Thorpe SR, Baynes JW, Chroneos ZC (1993) The design and application of residualizing labels for studies of protein catabolism. FASEB J 7:399-405
26. Behr TM, Goldenberg DM, Becker W (1998) Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: Present status, future prospects and limitations. Eur J Nucl Med 25:201-212
27. Vegt E et al (2010) Renal toxicity of radiolabeled peptides and antibody fragments: Mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med 51:1049-1058
28. Hagenbuch B (2010) Drug uptake systems in liver and kidney: A historic perspective. Clin Pharmacol Ther 87:39-47
29. Decristoforo C, Mather SJ (1999) 99m-Technetium- labelled peptide-HYNIC conjugates: Effects of lipophilicity and stability on biodistribution. Nucl Med Biol 26:389-396
30. Wilbur DS (1992) Radiohalogenation of proteins: An overview of radionuclides, labeling methods, and reagents for conjugate labeling. Bioconjug Chem 3:433-470
31. Sundin J et al (1999) High yield direct 76 Br-bromination of monoclonal antibodies using chloramine-T. Nucl Med Biol 26: 923-929
32. Nikula TK et al (1995) Impact of the high tyrosine fraction in complementarity determining regions: Measured and predicted effects of radioiodination on IgG immunoreactivity. Mol Immunol 32:865-872
33. Steffen AC et al (2005) In vitro characterization of a bivalent anti-HER-2 Af fi body with potential for radionuclide-based diagnostics. Cancer Biother Radiopharm 20:239-248
34. Tolmachev V et al (2009) Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Af fi body molecules. Eur J Nucl Med Mol Imaging 36: 692-701
35. Camera L et al (1994) Evaluation of the serum stability and in vivo biodistribution of CHXDTPA and other ligands for yttrium labeling of monoclonal antibodies. J Nucl Med 35: 882-889
36. Tolmachev V et al (2008) Evaluation of a maleimido derivative of CHX-ADTPA for site-specific labeling of Af fi body molecules. Bioconjug Chem 19:1579-1587
37. Kelly MP et al (2009) Therapeutic ef fi cacy of 177 Lu-CHX-A?-DTPA- hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate 69:92-104
38. De Leon-Rodriguez LM, Kovacs Z (2008) The synthesis and chelation chemistry of DOTA-peptide conjugates. Bioconjug Chem 19:391-402
39. Anderson CJ et al (2008) Cross-bridged macrocyclic chelators for stable complexation of copper radionuclides for PET imaging. Q J Nucl Med Mol Imaging 52:185-192
40. Wållberg H, Orlova A (2008) Slow internalization of anti-HER2 synthetic Af fi body monomer 111 In-DOTA-Z HER2:342-pep2 : Implications for development of labeled tracers. Cancer Biother Radiopharm 23:435-442
41. Ahlgren S et al (2008) Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant Af fi body molecules. Bioconjug Chem 19:235-243
42. Tran TA et al (2009) Design, synthesis and biological evaluation of a multifunctional HER2- specific Af fi body molecule for molecular imaging. Eur J Nucl Med Mol Imaging 36:1864-1873
43. Tolmachev V et al (2009) Af fi body molecules for epidermal growth factor receptor targeting in vivo: Aspects of dimerization and labeling chemistry. J Nucl Med 50:274-283
44. Orlova A et al (2006) Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 Af fi body for single-photon imaging of HER2 expression in tumors. J Nucl Med 47:512-519
45. Orlova A et al (2009) On the selection of a tracer for PET imaging of HER2-Expressing tumors: Direct comparison of a 124 I-labeled Af fi body molecule and trastuzumab in a murine xenograft model. J Nucl Med 50:417-425
46. Kramer-Marek G et al (2008) [ 18 F]FBEMZ HER2:342 -Af fi body molecule-A new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 35:1008-1018
47. Cheng Z et al (2008) Small-Animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18 F-labeled protein scaffold molecules. J Nucl Med 49:804-813
48. Tolmachev V et al (2007) Af fi body molecules: Potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther 7:555-568
49. Orlova A et al (2007) Update: Af fi body molecules for molecular imaging and therapy for cancer. Cancer Biother Radiopharm 22:573-584
50. Tolmachev V et al (2006) 111 In-benzyl-DTPAZ HER2:342 , an Af fi body-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 47:846-853
51. Orlova A et al (2007) Synthetic Af fi body molecules: A novel class of af fi nity ligands for molecular imaging of HER2-Expressing malignant tumors. Cancer Res 67:2178-2186
52. Engfeldt T et al (2007) Imaging of HER2- expressing tumours using a synthetic Af fi body molecule containing the 99m Tc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging 34:722-733
53. Wang Y, Liu X, Hnatowich DJ (2007) An improved synthesis of NHS-MAG3 for conjugation and radiolabeling of biomolecules with 99m Tc at room temperature. Nat Protoc 2:972-978
54. Lister-James J, Moyer BR, Dean RT (1997) Pharmacokinetic considerations in the development of peptide-based imaging agents. Q J Nucl Med 41:111-118
55. Engfeldt T et al (2007) 99m Tc-chelator engineering to improve tumour targeting properties of a HER2-specific Af fi body molecule. Eur J Nucl Med Mol Imaging 34:1843-1853
56. Tran T et al (2007) 99m Tc-maEEE-Z HER2:342 , an Af fi body molecule-based tracer for the detection of HER2 expression in malignant tumors. Bioconjug Chem 18:1956-1964
57. Ekblad T et al (2008) Development and preclinical characterisation of 99m Tc-labelled Af fi body molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging 35:2245-2255
58. Tran TA et al (2008) Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99m Tc-labeled anti-HER2 Af fi body molecules. Bioconjug Chem 19:2568-2576
59. Tran T et al (2007) In vivo evaluation of cysteine-based chelators for attachment of 99m Tc to tumor-targeting Af fi body molecules. Bioconjug Chem 18:549-558
60. Ahlgren S et al (2009) Targeting of HER2- expressing tumors with a site-specifically 99m Tclabeled recombinant Af fi body molecule, Z HER2:2395 , with C-terminally engineered cysteine. J Nucl Med 50:781-789
61. Wållberg H et al (2011) Molecular design and optimization of 99m Tc-labeled recombinant Af fi body molecules improves their biodistribution and imaging properties. J Nucl Med 52: 461-469
62. Feldwisch J et al (2010) Design of an optimized scaffold for Af fi body molecules. J Mol Biol 398:232-247
63. Zheng D, Aramini JM, Montelione GT (2004) Validation of helical tilt angles in the solution NMR structure of the Z domain of Staphylococcal protein A by combined analysis of residual dipolar coupling and NOE data. Protein Sci 13:549-554
64. Ahlgren S et al (2010) Targeting of HER2- expressing tumors using 111 In-ABY-025, a second-generation Af fi body molecule with a fundamentally reengineered scaffold. J Nucl Med 51:1131-1138
65. Christensen EI, Verroust PJ, Nielsen R (2009) Receptor-mediated endocytosis in renal proximal tubule. P fl ugers Arch 458:1039-1048
66. Tolmachev V et al (2007) Radionuclide therapy of HER2-positive microxenografts using a 177 Lu-labeled HER2-specific Af fi body molecule. Cancer Res 67:2773-2782
67. Mume E et al (2005) Evaluation of ((4-hydroxyphenyl) ethyl)maleimide for site-specific radiobromination of anti-HER2 Af fi body. Bioconjug Chem 16:1547-1555
68. Orlova A et al (2010) 186 Re-maSGS-Z HER2:342 , a potential Af fi body conjugate for systemic therapy of HER2-Expressing tumours. Eur J Nucl Med Mol Imaging 37:260-269
69. Johansson MU et al (2002) Structure, specificity, and mode of interaction for bacterial albumin-binding modules. J Biol Chem 277:8114-8120
70. Lejon S et al (2004) Crystal structure and biological implications of a bacterial albumin binding module in complex with human serum albumin. J Biol Chem 279:42924-42928
71. Andersen JT et al (2011) Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem 286:5234-5241
72. Nguyen A et al (2006) The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of af fi nity for albumin. Protein Eng Des Sel 19:291-297
73. Jonsson A et al (2008) Engineering of a femtomolar af fi nity binding protein to human serum albumin. Protein Eng Des Sel 21:515-527
74. Hopp J et al (2010) The effects of af fi nity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody- ABD fusion protein. Protein Eng Des Sel 23:827-834
75. Goetsch L et al (2003) Identi fi cation of B- and T-cell epitopes of BB, a carrier protein derived from the G protein of Streptococcus strain G148. Clin Diagn Lab Immunol 10:125-132
76. Singh H, Raghava GP (2001) ProPred: Prediction of HLA-DR binding sites. Bioinformatics 17:1236-1237
77. Nielsen M, Lund O (2009) NN-Align. An Artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics 10:296
78. Ekblad T et al (2009) Positioning of 99m Tcchelators Influences radiolabeling, stability and biodistribution of Af fi body molecules. Bioorg Med Chem Lett 19:3912-3914
79. Tolmachev V et al (2010) Imaging of EGFR expression in murine xenografts using sitespecifically labelled anti-EGFR 111 In-DOTAZ EGFR:2377 Af fi body molecule: Aspect of the injected tracer amount. Eur J Nucl Med Mol Imaging 37:613-622
80. Namavari M et al (2008) Direct site-specific radiolabeling of an Af fi body protein with 4-[ 18 F] fl uorobenzaldehyde via oxime chemistry. Mol Imaging Biol 10:177-181
81. Wållberg H et al (2010) Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys 61 ]- Z HER2:2395 -Cys Af fi body molecule for targeting of HER2-Expressing tumors. Mol Imaging Biol 12:54-62
82. Cheng Z et al (2010) 64Cu-labeled Af fi body molecules for imaging of HER2 expressing tumors. Mol Imaging Biol 12:316-324
83. Miao Z et al (2010) Small-Animal PET imaging of human epidermal growth factor receptor positive tumor with a 64 Cu labeled Af fi body protein. Bioconjug Chem 21:947-954
84. Tolmachev V et al (2010) A HER2-binding Af fi body molecule labelled with 68 Ga for PET imaging: Direct in vivo comparison with the 111 In-labelled analogue. Eur J Nucl Med Mol Imaging 37:1356-1367
85. Fortin MA et al (2007) Labelling chemistry and characterization of [ 90 Y/ 177 Lu]-DOTAZ HER2:342-3 Af fi body molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. Int J Mol Med 19:285-291
86. Tolmachev V et al (2009) The Influence of Bz-DOTA and CHX-A?-DTPA on the biodistribution of ABD-fused anti-HER2 Af fi body molecules: Implications for 114m In-mediated targeting therapy. Eur J Nucl Med Mol Imaging 36:1460-1468
87. Steffen AC et al (2007) Biodistribution of 211 At labeled HER-2 binding Af fi body molecules in mice. Oncol Rep 17:1141-1147
88. Sandberg D et al (2011) First-In-human wholebody HER2-receptor mapping using Af fi body molecular imaging. Cancer Res 71[24Supl.]: 273s Abstract P2-09-01